Reviewing Rigel Pharmaceuticals Inc. (RIGL)’s and Its Peers results

As Biotechnology company, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) is competing with its competitors based on the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Institutional & Insider Ownership

Rigel Pharmaceuticals Inc. has 96.5% of its shares held by institutional investors & an average of 50.88% institutional ownership for its peers. 0.2% of Rigel Pharmaceuticals Inc. shares are held by company insiders. Comparatively, 8.18% of all Biotechnology companies shares are held by company insiders.

Profitability

On first table we have Rigel Pharmaceuticals Inc. and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rigel Pharmaceuticals Inc. -1,497.44% -97.70% -82.60%
Industry Average 1,464.25% 88.44% 21.62%

Earnings & Valuation

In next table we are contrasting Rigel Pharmaceuticals Inc. and its competitors’ top-line revenue, valuation and net profit.

Net Income Gross Revenue Price/Earnings Ratio
Rigel Pharmaceuticals Inc. 99.58M 6.65M 0.00
Industry Average 34.08M 2.33M 58.78

Analyst Ratings

Table 3 shows breakdown of current ratings for Rigel Pharmaceuticals Inc. and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Rigel Pharmaceuticals Inc. 0 0 1 3.00
Industry Average 1.17 1.78 2.01 2.68

With average price target of $8.5, Rigel Pharmaceuticals Inc. has a potential upside of 279.46%. As a group, Biotechnology companies have a potential upside of 173.20%. Given Rigel Pharmaceuticals Inc.’s competitors higher possible upside, research analysts plainly believe Rigel Pharmaceuticals Inc. has less favorable growth aspects than its competitors.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Rigel Pharmaceuticals Inc. and its peers.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Rigel Pharmaceuticals Inc. -2.83% -12.42% -16.16% -14.6% -29.12% -29.12%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year Rigel Pharmaceuticals Inc. had bearish trend while Rigel Pharmaceuticals Inc.’s peers had bullish trend.

Liquidity

Rigel Pharmaceuticals Inc. has a Current Ratio of 6.1 and a Quick Ratio of 6.1. Competitively, Rigel Pharmaceuticals Inc.’s competitors Current Ratio is 7.68 and has 7.52 Quick Ratio. Rigel Pharmaceuticals Inc.’s rivals have better ability to pay short and long-term obligations than Rigel Pharmaceuticals Inc.

Risk and Volatility

A beta of 1.29 shows that Rigel Pharmaceuticals Inc. is 29.00% more volatile than S&P 500. Competitively, Rigel Pharmaceuticals Inc.’s competitors’ beta is 1.70 which is 70.08% more volatile than S&P 500.

Dividends

Rigel Pharmaceuticals Inc. does not pay a dividend.

Summary

Rigel Pharmaceuticals Inc.’s rivals show that they’re better in 3 of the 4 factors compared to the company itself.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisco, California.